Johnson & Johnson reports at least 72% PASI 90
Johnson & Johnson (JNJ) reported that its oral psoriasis drug ICOTYDE maintained at least 72% PASI 90 response rates through week 112 in the Phase 3 ICONIC-LEAD trial. JNJ shares rose 0.40% to $257.50. Alumis (ALMS) is also developing a psoriasis drug, envudeucitinib, with a planned U.S. application in Q4 2026.
How this was made
The 30-second read
Why it matters
Both companies receive positive clinical readouts, which could influence near‑term stock moves and sector sentiment.
Market read
New clinical data for two dermatology candidates may drive modest price reactions in JNJ and ALMS and lift biotech sentiment.
What to watch
Potential safety signals not disclosed; reimbursement and market adoption uncertainties could dampen impact.
Background
The article reports first‑time two‑year efficacy results for J&J's oral psoriasis drug ICOTYDE and compares them with Alumis' Phase 3 data, noting upcoming FDA filing timelines.
Ticker impact
Johnson & Johnson released two-year Phase 3 ICONIC-LEAD trial data showing ≥72% PASI 90 response, a first report of long-term efficacy for ICOTYDE.
likely modest upside as market prices in the durability data
First disclosure of two‑year efficacy, no new safety signals, and a small pre‑market price rise indicate positive sentiment.
Alumis Inc. disclosed its own Phase 3 psoriasis data and a planned Q4 2026 FDA filing, presented alongside JNJ's results.
potential modest upside as investors anticipate filing momentum
Data are new but less impactful than JNJ's; market may price in upcoming regulatory timeline.
Market effects
Biotech sector may see broader uplift as long‑term psoriasis data emerge, supporting other oral immunology programs.
U.S. biotech equities could benefit modestly; no clear regional bias.
Limited to investors tracking dermatology pipelines and oral IL‑23/TYK2 inhibitors.
Counterpoint
Durability data may not translate into commercial success if pricing or competition from biologics remains strong.
Key entities
- companyJohnson & Johnson
US‑listed healthcare conglomerate reporting long‑term psoriasis trial data.
- companyAlumis Inc.
Biotech firm with oral TYK2 inhibitor envudeucitinib, reporting Phase 3 data and filing plans.
